Fujiwara, Yu http://orcid.org/0000-0003-1406-2352
Horita, Nobuyuki
Harrington, Matthew
Namkoong, Ho
Miyashita, Hirotaka
Galsky, Matthew D.
Article History
Received: 18 January 2022
Accepted: 1 April 2022
First Online: 26 April 2022
Declarations
:
: None of the authors have a conflict of interest to report for the submitted work. M.D.G. reports stock from Rappta Therapeutics; a consulting/advisory role for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics, Basilea, Urogen, Infinity Pharmaceuticals, and Gilead; and institutional research funding from Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche.